Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
MannKind Corp(MNKD)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MNKD
10/23/2026: MNKD (1-star) is currently NOT-A-BUY. Pass it for now.
MannKind Corp is a specialty biopharmaceutical company that leverages its proprietary Technosphere platform to deliver inhaled therapies for diabetes and rare lung diseases. The company’s primary strength lies in its ability to commercialize unique drug delivery systems, bolstered by significant royalty-generating partnerships with major players like United Therapeutics. Its investment story centers on the successful adoption of Tyvaso DPI and the expansion of its orphan lung disease pipeline. However, the company faces notable risks, including intense competition from global pharmaceutical firms and the need to achieve consistent operating profitability. It is a speculative growth play best suited for investors comfortable with biotechnology volatility and long-term clinical development cycles.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through inhaled delivery innovation, but remains in a high-risk commercial phase. |
| Momentum investor | Mixed fit | The stock can experience sharp moves on news; a Momentum fit is conditional on positive clinical or commercial news cycles. |
| Value investor | Weak fit | The company is not currently valued based on traditional earnings or dividend metrics. |
| Dividend investor | Weak fit | MannKind does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | High volatility and the nature of the biotech industry make this unsuitable for low-risk capital preservation. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to regulatory announcements and commercial sales figures. |
| Valuation risk | Medium / high | Valuations are highly dependent on future growth assumptions rather than current earnings. |
| Competition risk (Pharmaceutical incumbents) | High | Large competitors can influence pricing and market access, pressuring MannKind's margins. |
| Business quality | Medium | The company has transitioned to a sustainable partnership-based revenue model but still faces execution hurdles. |
| Dividend income | Low / none | The company does not provide a source of regular income. |
| Execution risk | Medium / high | Success depends on commercializing niche products in markets dominated by global giants. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 21.54% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.03B USD | Price to earnings Ratio - | 1Y Target Price 8.08 |
Price to earnings Ratio - | 1Y Target Price 8.08 | ||
Volume (30-day avg) 4.8M shares | Beta 1.08 | 52 Weeks Range 2.23 - 6.51 | Updated Date 10/24/2026 |
52 Weeks Range 2.23 - 6.51 | Updated Date 10/24/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.14 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Endocrine Products | Direct sales of Afrezza and V-Go. | Revenue depends on how many patients switch to inhaled or wearable insulin. |
| Collaboration Revenue | Royalties and supply revenue from Tyvaso DPI (partnered with United Therapeutics). | This is a key high-margin revenue stream driven by the partner's market success. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 28.9 | Enterprise Value 1.43B | Price to Sales(TTM) 2.61 |
Enterprise Value 1.43B | Price to Sales(TTM) 2.61 | ||
Enterprise Value to Revenue 3.63 | Enterprise Value to EBITDA 70.14 | Shares Outstanding 321.54M | Shares Floating 297.60M |
Shares Outstanding 321.54M | Shares Floating 297.60M | ||
Percent Insiders 1.47 | Percent Institutions 57.11 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.